Zai Lab Limited (ZLAB) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders.
Is Zai Lab Limited stock overvalued or undervalued in 2026?
As of October 28, 2026, Zai Lab Limited (ZLAB) trades at $23.04 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Zai Lab Limited
Market cap $3B · 52 weeks $16 – $27 (15 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS $-0.56 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/Sales 3.5× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 8.8 %, fails.
- Market cap / Cash 3.7×, fails.
- Cash Runway 55 meses, passes.
- Total Debt 0.3×, passes.
- Annual cash burn $1.38, info.
Against its peers (reference peers) — Zai Lab Limited: P/E —; EV/EBITDA —; ROIC -29.3 %; $2.6B. HUTCHMED (China) Limited (P/E 140×; EV/EBITDA —; ROIC -2.1 %; $2.5B), ADMA Biologics, Inc. (P/E 16.1×; EV/EBITDA 11.0×; ROIC 27.6 %; $2.5B), Fortrea Holdings Inc. (P/E —; EV/EBITDA 40.3×; ROIC 0.6 %; $2.5B).
Profitability
| Return on Equity | -27.40% |
| Return on Invested Capital | -29.28% |
| Return on Assets | -17.49% |
| Gross Margin | 56.47% |
| Operating Margin | -58.73% |
| Net Margin | -41.86% |
Financial Health
| Debt / Equity | 0.42 |
| Current Ratio | 2.13 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -0.22 |
Price Performance
| 1 month | -11.15% |
| 3 months | +26.11% |
| Year-to-date | +30.61% |
| 1 year | -9.00% |
| 3 years | -9.26% |
| 5 years | -77.93% |
Related companies: HCM · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of ZLAB: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks